Leukemia & Lymphoma最新文献_第3页

Spontaneous regression of cutaneous T cell lymphoma in an HIV-positive patient. hiv阳性患者皮肤T细胞淋巴瘤的自发消退。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-02 DOI: 10.1080/10428194.2024.2433616

Xin Yun Teoh, Mazliha Mashor Mansor, Azura Mohd Affandi, Asmawiza Awang, Zuliatul Faizah Baharom

引用次数: 0

The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease. jun - rhoh轴在毛细胞白血病发病机制中的作用及其识别现有治疗方法的能力，这些治疗方法可以重新用于治疗复发或难治性疾病。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-17 DOI: 10.1080/10428194.2024.2438800

C Simon Shelley, Sylvie Galiègue-Zouitina, Leslie A Andritsos, Narendranath Epperla, Xavier Troussard

{"title":"The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease.","authors":"C Simon Shelley, Sylvie Galiègue-Zouitina, Leslie A Andritsos, Narendranath Epperla, Xavier Troussard","doi":"10.1080/10428194.2024.2438800","DOIUrl":"10.1080/10428194.2024.2438800","url":null,"abstract":"Hairy cell leukemia (HCL) is an indolent malignancy of mature B-lymphocytes. While existing front-line therapies achieve excellent initial results, a significant number of patients relapse and become increasingly treatment resistant. A major molecular driver of HCL is aberrant interlocking expression of the transcription factor JunD and the intracellular signaling molecule RhoH. Here we discuss the molecular basis of how the JunD-RhoH axis contributes to HCL pathogenesis. We also discuss how leveraging the JunD-RhoH axis identifies CD23, CD38, CD66a, CD115, CD269, integrin β7, and MET as new potential therapeutic targets. Critically, preclinical studies have already demonstrated that targeting CD38 with isatuximab effectively treats preexisiting HCL. Isatuximab and therapeutics directed against each of the other six new HCL targets are currently in clinical use to treat other disorders. Consequently, leveraging the JunD-RhoH axis has identified a battery of therapies that could be repurposed as new means of treating relapsed or refractory HCL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"637-655"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic and predictive impact of NOTCH1 mutation in chronic lymphocytic leukemia: a systematic review. NOTCH1突变对慢性淋巴细胞白血病预后和预测的影响：一项系统综述。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-27 DOI: 10.1080/10428194.2024.2441858

Veronica Guglielmana, Davide Rossi

引用次数: 0

Malignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome. 恶性肿瘤相关 HLH：严重高炎症综合征的机制、诊断和治疗。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-10 DOI: 10.1080/10428194.2024.2436037

Adi Zoref-Lorenz, Thomas E Witzig, James R Cerhan, Michael B Jordan

{"title":"Malignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome.","authors":"Adi Zoref-Lorenz, Thomas E Witzig, James R Cerhan, Michael B Jordan","doi":"10.1080/10428194.2024.2436037","DOIUrl":"10.1080/10428194.2024.2436037","url":null,"abstract":"Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome characterized by uncontrolled immune activation. While traditionally associated with genetic mutations affecting cytotoxic function, recent advances have highlighted the prevalence and significance of HLH in adults, particularly in hematologic malignancies. This review focuses on malignancy-associated HLH (M-HLH), a complex and challenging condition with a poor prognosis. The review explores four main subtypes of M-HLH: (1) HLH as the initial presentation of malignancy, (2) Chemotherapy Associated HLH, (3) Cytokine Release Syndrome (CRS) Associated HLH-like Syndrome, and (4) immune effector cell-associated HLH-like syndrome. Diagnosis is complicated by overlap with cancer symptoms and limitations of existing criteria. The Optimized HLH Inflammatory (OHI) index shows promise in early identification of hyperinflammation in new-onset hematologic malignancies. Treatment approaches must balance controlling hyperinflammation with addressing the underlying malignancy. Emerging therapies, including targeted agents like anakinra, ruxolitinib, and emapalumab, offer new management possibilities. This review examines the current understanding of M-HLH pathophysiology, diagnostic approaches, and treatment strategies for each subtype. It underscores the critical need for further research to unravel underlying mechanisms and establish evidence-based treatment protocols. Given the complexity of M-HLH, international collaborative efforts are essential to advance knowledge and improve patient outcomes.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"628-636"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial. 利妥昔单抗在未接受治疗的中国CD20+弥漫性大b细胞淋巴瘤患者中的药代动力学、疗效和安全性：一项II期随机对照试验

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2025-01-07 DOI: 10.1080/10428194.2024.2439525

Yan Gao, Liling Zhang, Sujun Gao, Yu Yang, Qingyuan Zhang, Huilai Zhang, Pengcheng He, Fei Li, Hongmei Jing, Susan Grange, Lilian Bu, Qianming Wang, Li Li, Huiqiang Huang

{"title":"Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial.","authors":"Yan Gao, Liling Zhang, Sujun Gao, Yu Yang, Qingyuan Zhang, Huilai Zhang, Pengcheng He, Fei Li, Hongmei Jing, Susan Grange, Lilian Bu, Qianming Wang, Li Li, Huiqiang Huang","doi":"10.1080/10428194.2024.2439525","DOIUrl":"10.1080/10428194.2024.2439525","url":null,"abstract":"Subcutaneous (SC) rituximab has demonstrated advantages over intravenous (IV) administration; however, insufficient data exist on its use with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in Chinese patients with diffuse large B-cell lymphoma (DLBCL). This multicenter, phase II, randomized, controlled study was conducted across China between February 2021 and October 2022. Fifty adult patients with previously untreated CD20-positive DLBCL were randomized to receive one cycle of IV rituximab and seven cycles of SC rituximab (RSC-CHOP; n = 26), or eight cycles of IV rituximab (RIV-CHOP; n = 24), combined with six or eight cycles of CHOP. Geometric mean ratio of trough rituximab serum concentration of SC to that of IV rituximab (Ctrough,SC/Ctrough,IV) at cycle 7 was 1.52 (90% CI: 1.28-1.79), demonstrating non-inferiority of Ctrough,SC. The complete response rate was similar in both treatment arms. SC rituximab is a viable option in Chinese patients with untreated CD20-positive DLBCL, potentially reducing administration burden (ClinicalTrials.gov identifier: NCT04660799).","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"680-690"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of comprehensive geriatric assessment, G8 and HOF score: how can we predict mortality in older patients with hematological malignancies?

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-04-01 DOI: 10.1080/10428194.2025.2482134

Fırat Akagündüz, Nurdan Şentürk Durmuş, Yasin Yıldız, Zeynep Beşışık Yılmaz, Çiğdem Alkaç, Büşra Can, Aslı Tufan

{"title":"Role of comprehensive geriatric assessment, G8 and HOF score: how can we predict mortality in older patients with hematological malignancies?","authors":"Fırat Akagündüz, Nurdan Şentürk Durmuş, Yasin Yıldız, Zeynep Beşışık Yılmaz, Çiğdem Alkaç, Büşra Can, Aslı Tufan","doi":"10.1080/10428194.2025.2482134","DOIUrl":"https://doi.org/10.1080/10428194.2025.2482134","url":null,"abstract":"Comprehensive geriatric assessment (CGA) is recommended for the evaluation of older patients with hematological malignancies. We investigated the association between CGA and mortality during hospitalization and at 1-year follow-up. Frailty was assessed by FRAIL scale, nutritional status by Mini-Nutritional Assessment-Short Form (MNA-SF), sarcopenia risk status by SARC-F. The Haema-Oncology Frailty (HOF) and Geriatric-8 (G8) scores were calculated prior to treatment. Most of the participants had malnutrition or risk of malnutrition based on the MNA-SF score. Half of the participants had risk of sarcopenia (n = 42, 50%). According to the FRAIL score, 51.2% (n:43) of the patients were frail and 38.1% (n:32) were pre-frail. Frailty was identified in 42.9% (n = 36) (HOF scores). Frailty (p = 0.007) and sarcopenia risk (p = 0.044) were linked to in-hospital mortality, the risk of 1-year mortality increased with higher HOF scores (p = 0.040). Findings from this study support the use of the FRAIL scale, SARC-F, and HOF score in clinical settings.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-31 DOI: 10.1080/10428194.2025.2482136

Mahek Garg, Ambika Satija, Yan Song, Eric M Sarpong, Benjamin Meade, Esteban Lemus-Wirtz, Katherine Gaburo, James E Signorovitch, Monika Raut, Katherine E Ryland

{"title":"Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data.","authors":"Mahek Garg, Ambika Satija, Yan Song, Eric M Sarpong, Benjamin Meade, Esteban Lemus-Wirtz, Katherine Gaburo, James E Signorovitch, Monika Raut, Katherine E Ryland","doi":"10.1080/10428194.2025.2482136","DOIUrl":"https://doi.org/10.1080/10428194.2025.2482136","url":null,"abstract":"Treatment patterns and all-cause and diffuse large B-cell lymphoma (DLBCL)-related healthcare resource use (monthly incidence) and costs (per patient per month [PPPM]) were estimated among patients with incident DLBCL in US Optum's de-identified Clinformatics® Data Mart Database (October 2015-December 2020). Among 3664 patients, 2279 (62%) had ≥1 line (1 L), 409 (18%) had 2 L, and 99 (4%) had 3 L treatment. Rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride, vincristine, and prednisone were most common in 1 L (75%) and 2 L (23%), although multiple regimens were used in 2 L and 3 L. With increasing lines of therapy, treatment duration decreased while hospitalization rates increased. Mean DLBCL-related hospitalization costs PPPM increased with each line (1 L: $6028; 2 L: $10,708; 3 L+: $20,483), accounting for increasing proportions of total all-cause costs (1 L: 30%; 2 L: 38%; 3 L+: 56%). Thus, DLBCL poses a substantial economic burden with fewer therapeutic alternatives, especially during later lines, highlighting the need for more effective treatment options.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-31 DOI: 10.1080/10428194.2025.2475327

Prokop Vodicka, Michal Masar, Katerina Benesova, Jan Koren, Pavel Klener, Kamila Polgarova, Jan Galko, Radek Jaksa, Vit Campr, Jitka Dlouha, Sarka Hrabetova, Petra Blahovcova, Magdalena Klanova, Marek Trneny

{"title":"The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis.","authors":"Prokop Vodicka, Michal Masar, Katerina Benesova, Jan Koren, Pavel Klener, Kamila Polgarova, Jan Galko, Radek Jaksa, Vit Campr, Jitka Dlouha, Sarka Hrabetova, Petra Blahovcova, Magdalena Klanova, Marek Trneny","doi":"10.1080/10428194.2025.2475327","DOIUrl":"https://doi.org/10.1080/10428194.2025.2475327","url":null,"abstract":"Symptoms of lymphomas include peripheral lymphadenopathy, B-symptoms, and other organ-specific symptoms; however, data on initial symptoms incidence in diffuse large B-cell lymphoma (DLBCL) remain limited. We aimed to investigate real-world patterns of initial DLBCL symptoms, correlating them with baseline characteristics and symptom onset-to-diagnosis interval. Patients with DLBCL diagnosed between 2010 and 2021 receiving R-CHOP were screened. 706 individuals with reported initial symptoms were analyzed. 682 (97%) patients had documented symptoms; remaining 24 patients (3%) had incidental findings discovered during examinations for unrelated reasons. Abdominal/gastrointestinal complaints were the most prevalent symptoms (26%), followed by peripheral lymphadenopathy (22%), and B-symptoms (13%). The median symptom-to-diagnosis interval was 10 weeks. Peripheral lymphadenopathy and testicular tumors correlated with low-risk characteristics, with testicular DLBCL featuring a shorter symptom-to-diagnosis interval. Limb pain/swelling and back pain were associated with high-risk characteristics and prolonged symptom-to-diagnosis interval. This analysis enhances our understanding of DLBCL symptomatology, aiding in timely recognition and management.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-7"},"PeriodicalIF":2.2,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Computational flow cytometry reveals a high prevalence of TRBC1-restricted CD8+ T-cell subsets.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-31 DOI: 10.1080/10428194.2025.2484643

Phillip C Nguyen, Tessa Potezny, Kah-Lok Chan, Surender Juneja, Kylie Baldwin, Vuong Nguyen, Neil Came, David A Westerman

引用次数: 0

Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-31 DOI: 10.1080/10428194.2025.2482130

Sofie Johansson Alm, Gustav Orrsjö, Giti Shah Barkhordar, Anna Rehammar, Anna Staffas, Erik Delsing Malmberg, Per-Ola Andersson, Hege Garelius, Mats Hardling, Lars Palmqvist, Linda Fogelstrand

{"title":"Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation.","authors":"Sofie Johansson Alm, Gustav Orrsjö, Giti Shah Barkhordar, Anna Rehammar, Anna Staffas, Erik Delsing Malmberg, Per-Ola Andersson, Hege Garelius, Mats Hardling, Lars Palmqvist, Linda Fogelstrand","doi":"10.1080/10428194.2025.2482130","DOIUrl":"https://doi.org/10.1080/10428194.2025.2482130","url":null,"abstract":"In acute myeloid leukemia with NPM1 mutation, analysis of measurable residual disease (MRD) with reverse transcription quantitative polymerase chain reaction (RT-qPCR) is recommended for response assessment and monitoring after treatment. For rare mutations in NPM1, this is not readily available. Therefore, we evaluated the prognostic value of deep sequencing covering all NPM1 exon 11 variants, using retrospectively analyzed bone marrow samples from 97 patients in remission during treatment. MRD positivity was defined as NPM1 mutation at ≥0.05% variant allele frequency based on a previous comparison with RT-qPCR. Deep sequencing MRD positivity at any time during consolidation predicted relapse-free survival (at 3 years: 23.1 ± 11.7% vs. 70.8 ± 6.1%, p < 0.001) and overall survival (at 3 years: 30.8 ± 12.8% vs. 63.8 ± 6.6%, p = 0.014). In multivariable analysis, MRD status during consolidation was the sole predictor for relapse. In conclusion, deep sequencing of NPM1 has high prognostic value and extends MRD monitoring to patients with rare mutations in NPM1.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0